Introduction
Interferon-g (IFN-g) is a pleiotropic cytokine that has antiviral and immunomodulatory functions, also known as a negative growth factor because of its function in tumor surveillance (Dighe et al., 1994; Kaplan et al., 1998) . Numerous reports indicated that IFN-g could exert direct antiproliferative effect on a wide variety of cell types. Loss of the responsiveness to IFN-g may occur in the context of malignant transformation (Maier et al., 1995; Rodig et al., 1998) .
IFN-g transduces signals from the cell surface to the interior of cells through a well-known pathway. Binding of IFN-g to its receptor results in phosphorylation of receptor-associated Janus-activated kinases (JAK), JAK1 and JAK2 (Stark et al., 1998) . Activated JAK1 and JAK2 phosphorylate signal transducers and activators of transcription 1 (STAT1), which forms a homodimer and translocates into the nucleus to activate the transcription of IFN-g -responsive elements (Darnell et al., 1994) . The IFN-g-induced inhibition of cell proliferation is critically dependent on the activation of STAT1. The antiproliferative effect of IFN-g has been observed in both human fibrosarcoma cells and murine fibroblasts, but not in mutagenized human cells lacking STAT1 nor in murine cells derived from STAT1-deficient mice (Bromberg et al., 1996; Chin et al., 1996) . It would be of interest to identify the molecular basis downstream of STAT1 that is involved in IFN-g-related growth inhibition.
Interferon-induced transmembrane protein 1 (IFITM1), also known as 9-27 or Leu13, is a member of the IFN-inducible transmembrane protein family. Transcription of IFITM1 is responsive to IFN-g, as well as IFN-a (Friedman et al., 1984; Kelly et al., 1985) . The IFITM1 mRNA is stable, and no effect of IFN-g on mRNA stability was detected (Ackrill et al., 1991) , indicating that IFN-g induces the de novo synthesis of IFITM1. An interferon-stimulated response element (ISRE) in the 5 0 flanking region of IFITM1 gene can confer both IFN-a and IFN-g inducibility to IFITM1 (Reid et al., 1989) . In STAT1 deficient cell line U3A, the inducibility of IFITM1 in response to IFN-g was abolished; however, in the parental normal cell 2fTGH, the IFN-g inducibility of IFITM1 was intact (Muller et al., 1993) . Further, enforced expression of STAT1 in U3A can restore the inducibility of IFITM1 in response to IFN-g (Muller et al., 1993) . These findings demonstrated the transcriptional induction of IFITM1 in response to IFN-g requires STAT1.
In the lymphoid tissues, IFITM1 protein is a component of protein complexes involved in homotypic adhesion and the transduction of antiproliferative signals (Evans et al., 1990; Bradbury et al., 1992; Deblandre et al., 1995) . Moreover, it has been reported that transcriptional expression of IFITM1 is downregulated in low-grade diffuse astrocytomas and breast cancer (Huang et al., 2000; Abba et al., 2004) . In this study, we report that IFITM1 mediates the antiproliferative effect of IFN-g and arrests cell proliferation in a p53-dependent manner. A critical role of IFITM1 in the antiproliferative action of IFN-g is hypothesized.
Results

IFITM1
mediates IFN-g-induced inhibition of cell proliferation IFITM1 was first discovered in T98G neuroblastoma cells that express the mRNA in response to interferon stimulation (Friedman et al., 1984; Reid et al., 1989) . In hepatoma line BEL-7404, IFITM1 mRNA and protein were highly inducible by IFN-g in a dose-dependent manner ( Supplementary Figure 1a and b) . Similar observations were made in non-malignant hepatocyte line Chang liver stimulated with IFN-g (data not shown), although endogenous expression of IFITM1 was low in BEL-7404 cells and much higher in Chang liver cells (Supplementary Figure 2) .
IFN-g inhibited cell proliferation in a time-dependent manner in both BEL-7404 and Chang liver cells (Figure 1a) . To determine the role of IFITM1 in the antiproliferative action of IFN-g, IFITM1 was silenced in BEL-7404 and Chang liver cells using an RNA interference (RNAi) approach (Figure 1b) , even in the presence of IFN-g treatment (Figure 1c ). The antiproliferative effect of IFN-g was significantly blocked in IFITM1 RNAi cells (Figure 1d ). The weak growth inhibition of high-dose IFN-g observed in IFITM1 RNAi cells might result from the incomplete depletion of induced IFITM1 (Figure 1c ).
Transient transfection of IFITM1 reduced growth rates of BEL-7404 and QSG-7701 cells (Figure 2a) , the hepatoma lines with low-endogenous expression of IFITM1 (Supplementary Figure 2) . Consistently, stable IFITM1 RNAi cells derived from Chang liver had a faster growth rate than its parental and control cells (Figure 2b ). It was suggested that IFITM1 negatively regulates cell proliferation. Taken together, these results demonstrated the essential role of IFITM1 in the antiproliferative action of IFN-g.
Suppression of IFITM1 may be related to tumorigenesis
Chang liver cells are derived from normal liver tissue and are not tumorigenic in nude mice. However, IFITM1 knockdown derivatives of Chang liver generated tumors in nude mice 6 weeks after injection, whereas no tumor was observed in nude mice injected with control cells (Figure 2c ).
To further explore the relationship between IFITM1 and tumorigenesis, messenger RNA levels of IFITM1 in clinical hepatocellular carcinoma (HCC) samples and the paired normal liver tissues were measured using quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR), calibrated by the expression level of b-actin. It was observed that in 20 out of 28 HCC samples tested, the IFITM1 mRNA was reduced to less than 70% of the paired normal liver tissues from the same patient, whereas in the rest eight HCC samples, IFITM1 transcript was similar in tumor and in the paired liver tissues (Figure 2d ). No significant association of IFITM1 mRNA level with sex, age and pathological stage was observed (data not shown). These results suggested that IFITM1 may play an important role in preventing tumorigenesis.
IFITM1 inhibits ERK activation
Mitogenic stimulation by growth factors usually activates the extracellular signal-regulated kinase (ERK) pathway. Sustained activation of this pathway is necessary for cell proliferation (Pages et al., 1993; Marshall, 1999) . In order to investigate the mechanism of IFITM1-caused growth inhibition, activity of ERK was examined in IFITM1-overexpressed or RNAi cells. In BEL-7404 and human embryonic kidney (HEK) 293 cells, endogenous phosphorylated ERK level was inhibited by overexpression of IFITM1 (Figure 3a and data not shown). Employing the PathDetect Elk transReporting System, we further demonstrated that ectopically expressed IFITM1 could inhibit ERK-mediated transcription in BEL-7404 cells (Figure 3b ). Consistently, the activated ERK level in IFITM1 RNAi cells derived from Chang liver was significantly increased compared to that of control cells (Figure 3c ).
Although IFITM1 inhibited ERK activation, IFN-g affected ERK in a complicated manner. In BEL-7404 cells, IFN-g induced a rapid activation of ERK in the first 3 h when IFITM1 was not induced (Figure 3d ). Associated with the induction of IFITM1, ERK activation was reduced to untreated control level. However, in IFITM1 RNAi cells, the IFN-g-induced activation of ERK was longer than that in the wild-type cells (Figure 3d and e). These observations suggested that IFITM1 would serve as a negative regulator of mitogen-activated protein (MAP) kinase signaling that is rapidly activated by IFN-g.
IFITM1 arrests cell cycle progression in the G1 phase in a p53-dependent manner We have observed that IFITM1 can control cell proliferation. The role of IFITM1 in cell cycle progression was further studied. It is known that tumor suppressor p53 plays a pivotal role in the regulation of cell growth arrest, and mutation in p53 and inactivation of p53 through interactions with viral or cellular proteins are the most frequent alterations observed in tumor cells (Levine, 1997) . Ectopically expressed IFITM1 caused cell cycle arrest in the G1 phase in BEL-7404 and QSG-7701 cells (Figure 4a, upper panel) . Sequencing the RT-PCR-amplified p53 transcripts found no mutation in their coding regions, and p53 RNAi cells (Figure 4c ). Thus, these results demonstrated that IFITM1 arrested cell cycle progression in the G1 phase in a p53-dependent manner.
IFITM1 enhances the transcriptional activity of p53 and stabilizes p53 protein by inhibiting p53 phosphorylation at Thr55
The observation that IFITM1 arrested cell cycle in a p53-dependent manner prompted us to examine whether IFITM1 regulates the transcriptional activity of p53. In Saos-2 cells with no endogenous p53, IFITM1 could not independently activate p53-responsive element in a reporter system. However, IFITM1 significantly enhanced the transcriptional activity of ectopically expressed p53 (Figure 5a, left panel) . In IFITM1-overexpressed BEL-7404 cells, both endogenous and ectopically expressed p53 activities were mildly increased ( Figure 5a , right panel). As an indicator of p53 activation (el-Deiry et al., 1993), p21 was up-regulated by ectopically expressed IFITM1 in both protein and mRNA levels (Figure 5b and c). Interestingly, IFITM1 did induce a slight increase of p53 protein level, but not its mRNA level (Figure 5b and c). The results suggested that IFITM1 might regulate the stability of p53 protein.
The stability of endogenous p53 was further measured in BEL-7404 cells, in the presence of the protein synthesis inhibitor cycloheximide (CHX) (Sigma), with or without ectopically expressed IFITM1. Significantly, the increased stability of p53 protein was observed in IFITM1-transfected cells (Figure 6a ). These results demonstrated that IFITM1 stabilizes p53 protein in vivo, and suggested the increased reporter activity in the presence of IFITM1 is due, at least partly, to this effect.
It was previously reported that phosphorylation on Thr55 mediates degradation of p53 protein, and introduction of the degradation-resistant mutant T55A into cells results in an increased G1 arrest than the wild-type p53 (Li et al., 2004) . Moreover, activation of ERK can phosphorylate p53 at Thr55 in response to doxorubicin (Yeh et al., 2001 (Yeh et al., , 2004 . Our observations that IFITM1 stabilized p53 protein and inhibited activity of ERK promoted us to investigate whether IFITM1 affects phosphorylation of p53 at Thr55. Reduced level of Thr55 phosphorylated p53, accompanied with less phosphorylated ERK and increased p21 protein level, were observed in BEL-7404 cells ectopically expressed IFITM1 (Figure 6b ), suggesting that Thr55 phosphorylation of p53 was inhibited by the IFITM1 overexpression. Further, the half-life of wildtype p53 or mutant T55A, in the presence or absence of IFITM, was measured in Saos-2 cells. As expected, the half-life of T55A was significant longer than p53 wild type, and the ectopically expressed IFITM1-stabilized wild-type p53, but not the mutated p53 (Figure 6c ). Taken together, these results suggested that IFITM1 may arrest cell cycle by inhibiting p53 phosphorylation at Thr55, thus stabilizing p53 protein, increasing the overall activity of cellular p53, and inducing p21 expression.
p53 is involved in the antiproliferative action of IFN-g Given the observations of IFITM1 mediating the antiproliferative action of IFN-g and arresting cell cycle in a p53-dependent manner, we would like to investigate the role of p53 in the IFN-g-induced growth arrest. IFN-g inhibited cell proliferation much more significantly in p53-positive cells, BEL-7404 and QSG-7701, than in p53-negative cells, HeLa and Saos-2 (Figure 7a ). In BEL-7404 p53 RNAi cells, the antiproliferative effect of IFN-g became much weaker than in the parental and control cells (Figure 7b) . The results demonstrated that p53 is an important element, downstream of IFITM1, involved in IFN-g-induced growth inhibition.
Discussion
IFITM1 is an important factor in growth control IFITM1 gene product was initially identified as Leu-13, a leukocyte antigen that is a part of a membrane complex involved in the transduction of antiproliferative and homotypic adhesion signals in lymphocytes (Chen et al., 1984; Takahashi et al., 1990; Bradbury et al., 1992; Matsumoto et al., 1993) . Monoclonal antibody to the IFITM1 triggers aggregation and inhibits proliferation of leukemic B cells (Evans et al., 1990) .
Here, we present evidences that IFITM1 can inhibit cell growth in human tumor cells. Overexpression of IFITM1 inhibited cell proliferation in hepatoma cells, consistent with previous unsuccessful attempts to establish cell lines stably expressing IFITM1 (Deblandre et al., 1995; Alber and Staeheli, 1996) . Suppression of IFITM1 accelerated cell growth, and conferred tumorigenicity to normal liver cells in nude mice. All these data point to a hypothesis that IFITM1 is a negative regulator of cell proliferation. Deletion of the p15.5 region of human chromosome 11 is implicated in the pathogenesis of a number of human cancers. RH mapping localized human IFITM1 gene to chromosome region 11p15.5 between D11S2071 and HRAS. Loss of heterozygosity in this region was observed in several solid tumors, including breast cancer, ovarian cancer, lung cancer and BeckwithWiedemann syndrome (Negrini et al., 1995; Tran and Newsham, 1996; Catchpoole et al., 1997; Lu et al., 1997; O'Briant and Bepler, 1997; Karnik et al., 1998) . We detected downregulated IFITM1 expression in 20 out of 28 clinical hepatoma samples, consistent with the reported transcriptional downregulation of IFITM1 in low-grade diffuse astrocytomas and breast cancer (Huang et al., 2000; Abba et al., 2004) . Recently, it was suggested that high IFITM1 expression correlated with improved survival in chronic myeloid leukemia patients (Akyerli et al., 2005) . The role of IFITM1 in carcinogenesis thus became an interesting issue for further investigation.
Role of IFITM1 in IFN-g-induced antiproliferative action IFN-g has long been thought to be a potential tool for treating human cancer; however, the molecular basis of IFN-g action in cancer treatment remains elusive. Without the identification of relevant target molecules, it will be difficult to understand the results of clinical trials of IFN-g in a heterogeneous patient population. Antitumor effects of IFN-g include directly affecting proliferation, indirectly modulating immunomodulatory and antiangiogenic responses of tumor cells via distinct and separate mechanisms (Stark et al., 1998) . Thus, the current study undertook a detailed attempt to investigate one of these aspects, the mechanisms of direct antiproliferative action of IFN-g.
IFN-g controls cell growth through signal molecules, including IFN-g receptor, JAK and STAT1 (Maier et al., 1995; Bromberg et al., 1996; Chin et al., 1996; Buard et al., 1998; Rodig et al., 1998) . But so far, little is known about the signal events downstream of STAT1. Our data demonstrated that IFITM1 is induced by IFN-g, and mediates the IFN-g-induced growth inhibition in a p53-dependent manner. It was previously reported that p53 is also required for the IFN-g-induced growth inhibition in primary cultured hepatocytes (Kano et al., 1999) . In BEL-7404 cells, p53 is involved in both IFN-g-and IFITM1-induced growth arrest, consistent with the reported result.
We observed that IFITM1 enhances p53 transcriptional activity and induces upregulation of p21, which is a well-studied IFN-g-inducible protein that arrests cell cycle in the G1/S phase (Chin et al., 1996; Mandal et al., 1998) . However, we did not find the direct interaction between IFITM1 and p53 using co-immunoprecipitation analysis in HEK 293T cells (data not shown). Possible mechanisms through which IFITM1 affects p53 may include: (1) IFITM1 stabilizes p53 probably by inhibiting its Thr55 phosphorylation and (2) IFITM1 inhibits activation of ERK pathway, which may cause induction of Mdm2, a major negative regulator of p53, and therefore result in suppression of p53 (Ries et al., 2000; Halaschek-Wiener et al., 2004) . We examined Hdm2 (human Mdm2) levels in the IFITM1-overexpressed BEL-7404 cells. Like p21, Hdm2 is also a sensitive indicator of p53 activation (Zauberman et al., 1995) . However, unlike p21, both mRNA and protein levels of Hdm2 were not significantly changed in the ectopic IFITM1-expressed cells (Supplementary  Figure 3) . These results suggested that IFITM1 might have effects on Hdm2 levels via other mediators, such as ERK, besides p53. The defined modulation of Hdm2 levels by the effects of IFITM1 would need further studies.
However, p53 may not be the only pathway through which IFN-g inhibits cell growth. As shown in Figure 7b , silence of p53 expression reduced, yet did not totally block the antiproliferative action of IFN-g in BEL-7404 cells. IFN-g might inhibit cell proliferation through other pathways, such as suppression of oncogene c-myc (Matsushita et al., 2006) 1997; Notari et al., 2006) . Further, expression of c-myc in response to clone-stimulating factor 1 requires ERK signaling (Cheng et al., 1999) . These findings suggested that IFITM1 might inhibit c-myc expression by inhibiting ERK activity. In addition, IFN-g may affect cell proliferation associated with downregulating of oncogene neu/Her2 expression (Kominsky et al., 2000) . However, the defined mechanism of downregulation of neu/Her2 by IFN-g would need further studies.
Previous studies reported that IFN-g can induce reversion of Ras-transformed NIH-3T3 cells (Seliger et al., 1991) . However, IFN-g does induce a rapid activation of MAP kinase signal cascade via an unidentified pathway in many cell types (Liu et al., 1994; Sakatsume et al., 1998; Stancato et al., 1998) . We demonstrated that IFITM1 inhibited ERK activation in BEL-7404 cells. Further, in IFITM1 RNAi cells, the IFN-g-induced activation of ERK is longer than that in the wild-type control cells. These findings suggested that IFITM1 would serve as a negative regulator of MAP kinase signaling that is rapidly activated by IFN-g, and mediated cell growth arrest.
IFITM1 was originally identified as a leukocyte surface antigen in lymphocytes (Chen et al., 1984) . However, it was reported that intracellular distribution of IFITM1 resembled that of cytoskeleton-associated proteins (Alber and Staeheli, 1996) . We examined the subcellular localization of IFITM1 protein in BEL-7404 and Chang liver cells. Under a confocal microscopy, both endogenous and ectopically expressed IFITM1 were allocated mostly on endoplasmic reticulum (ER), but not on cell surface, even in the presence of IFN-g treatment (Supplementary Figure 4) . A number of cytoskeleton-or ER-associated proteins play an important role in MAP kinase or p53 signaling pathway, such as Nck and caveolin1 (Galbiati et al., 1998 (Galbiati et al., , 2001 Schlegel et al., 2001; Nguyen et al., 2004) . These findings provided a possible linkage between IFITM1 and ERK or p53 pathway, and suggested a diversified function of IFITM1 in different cell types.
Finally, we now provide a novel signal pathway through which IFN-g inhibits cell proliferation: IFN-g activates JAK-STAT1 signaling, leading to the induction of IFITM1 and the consequent functional activation of p53. This study identified, for the first time, an IFN-g-induced molecular target that mediates the antiproliferative action of IFN-g, bridged two wellknown signaling cascades, JAK-STAT and p53-p21, both of which play critical roles in tumor suppression, and could be helpful to evaluate the variable results of clinical trials of IFN-g in a heterogeneous patient population.
Materials and methods
Constructs
The coding region of the human IFITM1 gene was amplified from cDNA of Chang liver cells using appropriate specific primers, and cloned into pcDNA3.1B (Invitrogen, Paisley, UK) and pEGFP-N1 (Clontech, Palo Alto, CA, USA) vectors. In a similar manner, the entire coding region of human ERK2 and p53 was cloned into a pcDNA3.1B vector. From pcDNA3.1-p53 construct, the p53 mutant T55A was obtained using QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions.
Cells, cell culture, reagents and transfection BEL-7404 and QSG-7701 were purchased from Type Culture Collection of Chinese Academy of Sciences, Shanghai. Chang liver, HeLa and Soas-2 were purchased from American Type Culture Collection. These cells and their derivatives were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin. IFN-g was purchased from PeproTech Inc., London, UK. Plasmids were transfected into cells using Lipofectamine 2000 reagent (Invitrogen) according to manufacturer's instructions.
Cell viability measurement
Cell viability was measured by an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] method. Briefly, cells were seeded in 96-well plates, incubated until 20 ml MTT stock solution (5 mg/ml in 0.1 M phosphatebuffered saline (PBS)) was added to each well, followed by incubation at 371C for 4 h. The reaction was terminated by aspirating the medium. In each well, 150 ml dimethyl sulfoxide was added to dissolve the formazan crystals; plates were read at 492 nm on a microplate reader (Bio-Tek, Winooski, VT, USA).
Stable RNAi
Plasmids encoding small hairpin RNAs directed against human IFITM1 and p53 were constructed by cloning oligonucleotides targeting nucleotides 460-478 of IFITM1 sequence (NM_003641) or nucleotides 1026-1044 of p53 sequence (NM_000546) in pSUPER.retro.puro (Oligoengine, Seattle, Washington, USA), as described previously (Brummelkamp et al., 2002) . Oligonucleotides targeting green fluorescent protein (GFP) (GAACGGCATCAAGGTGAAC) was used as a control. BEL-7404 or Chang liver cells were transfected for 24 h and incubated in the medium containing 1 mg/ml puromycin for 10 days. Positive clones were tested by Western blot analysis.
Quantitative real-time RT-PCR assay Total RNA was isolated using TRIzol (Invitrogen), and reverse transcribed with Super-scriptase (Invitrogen). To measure mRNA level of IFITM1, a real-time PCR assay was performed on a DNA Engine Opticon 2 (MJ Research, Watertown, MA, USA) using the DyNAmo SYBR Green qPCR kit (Finnzymes Oy, Espoo, Finland), cDNAs and the appropriate primers (see Supplementary Information). All data were normalized to the b-actin mRNA level and expressed as mRNA relative change.
Western blot analysis
Immunoblotting was performed as described previously (Huang et al., 2002) with primary antibodies against p21, ERK, phosphor-ERK, phospho-p53 (Thr55), actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p53 (Upstate Biotechnology, Lake Placid, NY, USA), myc (Oncogene Science, Uniondale, NY, USA), or IFITM1 (Boster, Wuhan, China).
Cell cycle profile Cells were fixed in 70% ethanol, incubated with 50 mg/ml propidium iodide and 50 mg/ml RNase A for 30 min at 371C, and analysed on a FACStar Plus flow cytometer (Becton Dickinson, San Jose, CA, USA) using Cell Quest (BD Biosciences, San Jose, CA, USA) and ModFit LT (Verity Software House, Topsham, ME, USA).
For measuring the cell cycle distribution in cells expressing GFP fusion protein, cells were transfected with plasmids for 40 h, then fixed with 4% paraformaldehyde for 1 h at 41C followed by permeabilization with 0.1% Triton X-100 and 0.1% citrate sodium for 5 min on ice, and incubated with propidium iodide and RNase A as above. Cell cycle distributions were analysed as described previously (Galbiati et al., 2001) .
Tumorigenicity assay Cells (4 Â 10 6 ) in log growth phase were washed and suspended in 200 ml of sterile PBS on ice for subcutaneous injection into the flank of 4-6 weeks old BALB/c nude mice purchased from Shanghai Laboratory Animals Center of the Chinese Academy of Sciences. Mice were observed weekly for the visual appearance of tumors at injection sites, and tumors were harvested and weighed 8 weeks after injection. For each cell type, three mice were injected to avoid the individual differences in the nude mice.
Clinical samples
Clinical HCC samples at stages II and III by pathological examination were collected from Zhongshan Hospital immediately after surgery. The paired non-tumorous liver samples were 3 cm away from the edge of HCC lesions from the same patients. The 28 HCC patients (male/female, 22/6) were aged 32-74. Access to human tissues complied with both Chinese laws and the guidelines of the Ethics Committee.
Reporter gene assay PathDetect Elk trans-Reporting system vectors (pFR-Luc and pFA-Elk) were purchased from Stratagene (La Jolla, CA, USA). The luciferase reporter vector containing p53 binding sites was kindly provided by Dr B Vogelstein (Johns Hopkins University, Baltimore, MD, USA). For measuring ERK activation, BEL-7404 cells were co-transfected with ERK2-pcDNA3.1, pFR-Luc, pFA-Elk, pRL-TK (Promega, Madison, WI, USA), and increasing amounts of IFITM1 plasmid and cultured in 1% FBS for 36 h after transfection. For measuring p53 transcription activity, Saos-2 cells or BEL-7404 cells were co-transfected with the reporter plasmid, pRL-TK and either p53-pcDNA3.1 or empty vectors and cultured in 10% FBS for another 48 h. Firefly (ff-Luc) and Renilla (r-Luc) luciferase activities in lysates were measured by a dual luciferase assay system (Promega) following the manufacturer's protocol.
Statistical analysis
Data were analysed by Student's t-test for comparison of independent means, with pooled estimates of common variances. For all test, Po0.05 was considered significant.
